Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Share-based Compensation (2023 - 2025)

Kura Oncology (KURA) has disclosed Share-based Compensation for 3 consecutive years, with $11.4 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 31.53% to $11.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.1 million through Dec 2025, up 9.47% year-over-year, with the annual reading at $37.1 million for FY2025, 9.47% up from the prior year.
  • Share-based Compensation for Q4 2025 was $11.4 million at Kura Oncology, up from $11.0 million in the prior quarter.
  • The five-year high for Share-based Compensation was $11.4 million in Q4 2025, with the low at $6.8 million in Q1 2023.
  • Average Share-based Compensation over 3 years is $8.3 million, with a median of $8.1 million recorded in 2024.
  • Peak annual rise in Share-based Compensation hit 31.73% in 2025, while the deepest fall reached 17.57% in 2025.
  • Over 3 years, Share-based Compensation stood at $7.2 million in 2023, then rose by 20.43% to $8.6 million in 2024, then skyrocketed by 31.53% to $11.4 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $11.4 million, $11.0 million, and $6.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.